Trial reportSurgical endoscopy2026
Covered self-expandable metal stents in benign biliary strictures caused by chronic pancreatitis: a randomized controlled trial of 6 versus 12 months of stenting.
Trial report in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn chronic pancreatitis (CP), a symptomatic benign biliary stricture (BBS) evolves as an adverse event in 3-30%. Treatment by ERCP with a single plastic biliary stent has been disappointing. Multiple plastic stents are more successful but make the procedure more time consuming than treatment with a fully covered self-expandable metal stent (fcSEMS). The most efficient stenting duration of BBS caused by CP is not known. The aim of this multicenter prospective randomized study was to compare the safety and feasibility of 10 mm diameter fcSEMSs placed for 12 months versus 12 mm diameter fcSEMSs placed for 6 months in the treatment of BBS caused by CP.
methodsThe patients were randomized into two groups: either 10 mm diameter fcSEMS for 12 months or 12 mm diameter fcSEMS for 6 months. After stent removal, the patients were followed up at 6 and 24 months with liver function tests and abdominal ultrasound.
resultsA total of 62 consecutive patients undergoing ERCP for the treatment of BBS at six centers were enrolled. Four patients in the 10 mm group and five in the 12 mm group were excluded due to a diagnosis of pancreatic cancer, and two in the 10 mm and four in the 12 mm group were excluded because of death from other causes during the 2-year follow-up. In the 10 mm group, one stent became impacted in the bile duct necessitating hepaticojejunostomy; this patient was also excluded from the final analysis. The final sample size was 24 patients in the 10 mm group and 22 in the 12 mm group. In the 12 mm group, one stent migrated requiring re-stenting. Recurrent strictures occurred in 3 of 24 patients (13%) in the 10 mm group and in 4 of 22 patients (18%) in the 12 mm group (p = 0.694).
conclusionsBoth types of fcSEMS are effective in the treatment of BBS secondary to CP. However, the increased risk of pancreatic cancer in these patients should be taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.